Key result
VA-ECMO plus IABP was associated with lower in-hospital mortality compared to VA-ECMO alone or IABP alone in AMICS patients.
Why the study?
The effectiveness of concomitant intra-aortic balloon pump with veno-arterial extracorporeal membrane oxygenation in patients with acute myocardial infarction with cardiogenic shock is contested in the literature.
Does VA-ECMO plus IABP reduce in-hospital all-cause mortality in patients with acute myocardial infarction with cardiogenic shock compared to VA-ECMO alone or IABP alone?
Meta-Analysis (n=4,686)
Does VA-ECMO plus IABP reduce in-hospital all-cause mortality in patients with acute myocardial infarction with cardiogenic shock compared to VA-ECMO alone or IABP alone?
Concomitant use of VA-ECMO and IABP in AMICS patients is associated with reduced in-hospital and 30-day mortality and higher rates of weaning from VA-ECMO compared to either therapy alone.
Answers are grounded in this paper and cite their sources.
Concomitant IABP with VA-ECMO was associated with lower short-term mortality in AMICS; leaves open effects on weaning and need for prospective confirmation.
Background The effectiveness of a concomitant intra-aortic balloon pump (IABP) with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) intervention in acute myocardial infarction with cardiogenic shock (AMICS) patients is contested in the literature. This study sought to compare short-term mortality weaning rate from VA-ECMOin AMICS cases. Methods We conducted a literature review and compared the primary and secondary endpoints in the following treatment groups of AMICS patients: (1) VA-ECMO plus IABP vs. IABP alone and (2) VA-ECMO plus IABP vs. VA-ECMO alone. The primary endpoint was in-hospital all-cause mortality; while 30-days mortality, weaning from VA-ECMO, and vascular complications comprised secondary endpoints. Results VA-ECMO concomitant with IABP was administered to 3,580 (76.4%) patients, while IABP alone and VA-ECMO alone treatments accounted for 1.7% and 21.9% of the patients, respectively. We found that in-hospital mortality was significantly lower in patients treated with VA-ECMO plus IABP vs. VA-ECMO alone (odds ratio (OR) = 0.52; 95% Confidence Interval (CI) = 0.21–1.31; I-squared statistic ( I 2 = 30%) or IABP alone (OR = 0.20; 95% CI = 0.08–0.55; I 2 = 0%). Additionally, 30-days mortality was significantly lower in patients treated with VA-ECMO plus IABP vs. VA-ECMO alone (OR = 0.31; 95% CI = 0.25–0.40; I 2 = 0%) or IABP alone (OR = 0.24; 95% CI = 0.11–0.50; I 2 = 0%). A significant difference was observed in weaning from VA-ECMO in patients treated with VA-ECMO plus IABP vs. VA-ECMO alone (OR = 1.91; 95% CI = 1.09–3.33; I 2 = 0%). Conclusion In-hospital and 30-days mortality were significantly lower in AMICS patients treated with VA-ECMO plus IABP vs. VA-ECMO alone or IABP alone. VA-ECMO with concomitant IABP could increase the proportion of patients weaned from VA-ECMO, significantly reducing in-hospital mortality, without increasing complications.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) conducted a meta-analysis in Acute myocardial infarction with cardiogenic shock (AMICS) (n=4,686). VA-ECMO plus IABP vs. VA-ECMO alone or IABP alone was evaluated on In-hospital all-cause mortality (OR 0.52, 95% CI 0.21-1.31). VA-ECMO plus IABP was associated with lower in-hospital mortality compared to VA-ECMO alone or IABP alone in AMICS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: